Dual-time-point 18F-FDG PET/CT in patients with colorectal cancer: Clinical value of early delayed scanning

Annals of Nuclear Medicine

Volumn 26, Issue 6, 2012, Pages 492-500

  Miyake, Kanae K ^a   Nakamoto, Yuji ^a   Togashi, Kaori ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Dual time point FDG PET CT; Early delayed scan; Physiologic uptake

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; COLON; COLONOSCOPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DELAYED DIAGNOSIS; DIAGNOSTIC ACCURACY; DRUG UPTAKE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECTUM; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SMALL INTESTINE; URETER; WHOLE BODY SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; COLORECTAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84864711171     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0599-y     Document Type: Article

References (35)

1. Strauss LG, Klippel S, Pan L, Schonleben K, Haberkorn U, Dimitrakopoulou-Strauss A. Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection? Eur J Nucl Med Mol Imaging. 2007;34:868-77. (Pubitemid 46798955)
2. Nishiyama Y, Yamamoto Y, Fukunaga K, Kimura N, Miki A, Sasakawa Y, et al. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med. 2006;47:633-8. (Pubitemid 46768464)
3. Caprio MG, Cangiano A, Imbriaco M, Soscia F, Di Martino G, Farina A, et al. Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions. Radiol Med. 2010;115:215-24.
4. Tian R, Su M, Tian Y, Li F, Li L, Kuang A, et al. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions. Skeletal Radiol. 2009;38:451-8.
5. Demura Y, Tsuchida T, Ishizaki T, Mizuno S, Totani Y, Ameshima S, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med. 2003;44:540-8. (Pubitemid 39663420)
6. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer. 2000;89:2547-54. (Pubitemid 32011597)
7. Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28:696-703.
8. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 143-64.
9. Gutman F, Alberini JL, Wartski M, Vilain D, Le Stanc E, Sarandi F, et al. Incidental colonic focal lesions detected by FDG PET/CT. Am J Roentgenol. 2005;185:495-500.
10. Israel O, Yefremov N, Bar-Shalom R, Kagana O, Frenkel A, Keidar Z, et al. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med. 2005;46:758-62.
11. Drenth JP, Nagengast FM, Oyen WJ. Evaluation of (pre- )malignant colonic abnormalities: endoscopic validation of FDG-PET findings. Eur J Nucl Med. 2001;28:1766-9.
12. Kei PL, Vikram R, Yeung HW, Stroehlein JR, Macapinlac HA. Incidental finding of focal FDG uptake in the bowel during PET/CT: CT features and correlation with histopathologic results. Am J Roentgenol. 2010;194:W401-6.
13. Tatlidil R, Jadvar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology. 2002;224:783-7. (Pubitemid 34919813)
14. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics. 2004;24:1411-31. (Pubitemid 39329385)
15. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308-14. (Pubitemid 126789027)
16. Kamel EM, Thumshirn M, Truninger K, Schiesser M, Fried M, Padberg B, et al. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med. 2004;45:1804-10. (Pubitemid 47618435)
17. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61-77.
18. Yasuda S, Fujii H, Nakahara T, Nishiumi N, Takahashi W, Ide M, et al. 18F-FDG PET detection of colonic adenomas. J Nucl Med. 2001;42:989-92. (Pubitemid 32595293)
19. Soyka JD, Strobel K, Veit-Haibach P, Schaefer NG, Schmid DT, Tschopp A, et al. Influence of bowel preparation before 18F-FDG PET/CT on physiologic 18F-FDG activity in the intestine. J Nucl Med. 2010;51:507-10.
20. Stahl A, Weber WA, Avril N, Schwaiger M. Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen. Nuklearmedizin. 2000;39:241-5. (Pubitemid 32039700)
21. Emmott J, Sanghera B, Chambers J, Wong WL. The effects of N-butylscopolamine on bowel uptake: an 18F-FDG PET study. Nucl Med Commun. 2008;29:11-6. (Pubitemid 351339335)
22. Murphy R, Doerger KM, Nathan MA, Lowe VJ. Pretreatment with diphenoxylate hydrochloride/atropine sulfate (Lomotil) does not decrease physiologic bowel FDG activity on PET/CT scans of the abdomen and pelvis. Mol Imaging Biol. 2009;11: 114-7.
23. Chen YK, Chen JH, Tsui CC, Chou HH, Cheng RH, Chiu JS. Use of laxative-augmented contrast medium in the evaluation of colorectal foci at FDG PET. Radiology. 2011;259:525-33.
24. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412-7. (Pubitemid 32852620)
25. Toriihara A, Yoshida K, Umehara I, Shibuya H. Normal variants of bowel FDG uptake in dual-time-point PET/CT imaging. Ann Nucl Med. 2010;25:173-8.
26. Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology. 1998;206:755-60. (Pubitemid 28128526)
27. Mukai M, Sadahiro S, Yasuda S, Ishida H, Tokunaga N, Tajima T, et al. Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncol Rep. 2000;7:85-7.
28. Shin SS, Jeong YY, Min JJ, Kim HR, Chung TW, Kang HK. Preoperative staging of colorectal cancer: CT vs. integrated FDG PET/CT. Abdom Imaging. 2008;33:270-7. (Pubitemid 351537885)
29. Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum. 2000;43:759-67.
30. Kantorova I, Lipska L, Belohlavek O, Visokai V, Trubac M, Schneiderova M. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decisionmaking. J Nucl Med. 2003;44:1784-8. (Pubitemid 39663310)
31. Topal B, Flamen P, Aerts R, D'Hoore A, Filez L, Van Cutsem E, et al. Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol. 2001;27:175-9. (Pubitemid 32621731)
32. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol. 1997;4:613-20. (Pubitemid 127725488)
33. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004;240:1027-34.
34. Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol. 2002;20:388-95. (Pubitemid 34072520)
35. Fong Y, Saldinger PF, Akhurst T, Macapinlac H, Yeung H, Finn RD, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg. 1999;178:282-7.